术中多巴酚丁胺联合去甲肾上腺素预防脓毒性休克术后急性肾损伤:随机临床试验
该随机、开放标签试验在中国39家三级医院纳入584例接受手术源控制的成人脓毒性休克患者,比较术中静脉输注多巴酚丁胺(至多5 µg/kg/min)联合去甲肾上腺素与单用去甲肾上腺素。主要终点为术后7天内KDIGO标准新发AKI或术前AKI恶化,联合组22.8%(66/290) vs 单用组34.7%(102/294),校正风险比0.64(95%CI 0.49-0.83)。术后第1天SOFA评分更低、干预后1小时尿量更高,2期和3期AKI更少;心动过速(心率>100/min)在联合组更常见。提示术中联合多巴酚丁胺可减少术后AKI,但需权衡心动过速风险。
要点
- 成人脓毒性休克接受手术源控制者,术中多巴酚丁胺(至多5 µg/kg/min)联合去甲肾上腺素较单用去甲肾上腺素降低术后7天内新发或恶化AKI:22.8% vs 34.7%,ARR 0.64(95%CI 0.49-0.83)。
- 联合组2期AKI(4.8% vs 9.9%;ARR 0.48,95%CI 0.26-0.88)和3期AKI(7.9% vs 13.6%;ARR 0.56,95%CI 0.35-0.91)均低于单用去甲肾上腺素组。
- 联合组术后第1天SOFA评分更低(校正差值-0.53,95%CI -0.98至-0.07),干预后1小时尿量更高(校正差值0.55 mL/kg/h,95%CI 0.03-1.07)。
- 心动过速(心率>100/min)在联合组更常见,床旁需监测心率;11项次要终点中9项无显著差异。
- 适用人群为接受手术源控制的成人脓毒性休克患者;多巴酚丁胺为术中静脉输注、剂量至多5 µg/kg/min,非通用推荐剂量。
适用人群与场景
- 中国39家三级医院纳入的成人脓毒性休克患者,均接受手术源控制(surgical source control),年龄中位数67.5岁(IQR 55.0-76.0),女性32.9%(192/584)。
- 原文未提及排除人群、急诊/ICU/院前场景及病情阶段的进一步限定。
诊断标准与关键阈值
- 主要终点AKI采用KDIGO(Kidney Disease: Improving Global Outcomes)标准定义,为术后7天内新发AKI或术前AKI恶化。
- AKI分期按KDIGO标准分为2期和3期,原文报告了各期发生率但未列出具体肌酐/尿量界值。
处置流程与药物剂量
- 第一步:对接受手术源控制的成人脓毒性休克患者,术中静脉输注多巴酚丁胺(至多5 µg/kg/min)联合去甲肾上腺素。
- 第二步:对照组为单用去甲肾上腺素;原文未提及去甲肾上腺素的具体剂量、给药途径、频次或目标血压。
- 第三步:监测心率,因联合组心动过速(心率>100/min)更常见;原文未提及心动过速的具体处理措施。
- 第四步:术后7天内监测KDIGO定义的AKI(新发或恶化),并关注术后第1天SOFA评分及干预后1小时尿量。
红旗征与不能漏的情况
- 心动过速(心率>100/min)在联合组更常见,需警惕并监测。
- 原文未提及其他红旗征或不能漏诊的情况及对应处理。
研究设计与关键结果
- 研究类型:随机、开放标签临床试验,中国39家三级医院,2024年6月至2025年8月入组,随访至2025年11月15日;样本量584例(多巴酚丁胺+去甲肾上腺素组290例,单用去甲肾上腺素组294例)。
- 主要终点:术后7天内新发或恶化AKI,联合组22.8%(66/290) vs 单用组34.7%(102/294),校正风险比(ARR)0.64(95%CI 0.49-0.83)。
- 关键次要终点:术后第1天SOFA评分校正差值-0.53(95%CI -0.98至-0.07);干预后1小时尿量校正差值0.55 mL/kg/h(95%CI 0.03-1.07);2期AKI 4.8% vs 9.9%(ARR 0.48,95%CI 0.26-0.88);3期AKI 7.9% vs 13.6%(ARR 0.56,95%CI 0.35-0.91)。
- 不良事件:心动过速(心率>100/min)在联合组更常见;11项次要终点中9项无显著差异。
证据类型、等级与局限
- 证据类型:随机、开放标签临床试验(RCT),注册号NCT06462313。
- 局限:开放标签设计;原文未提及盲法、样本量计算或亚组分析;研究在中国39家三级医院进行,外推需谨慎。
对床旁实践的改变
- 对接受手术源控制的成人脓毒性休克患者,术中可考虑在去甲肾上腺素基础上加用多巴酚丁胺(至多5 µg/kg/min)以降低术后7天内新发或恶化AKI的风险。
- 加用多巴酚丁胺时需监测心率,因心动过速(心率>100/min)更常见;原文未提供心动过速的停药或减量阈值。
- 该策略不适用于原文未纳入的人群(如非手术源控制、非成人、非脓毒性休克);多巴酚丁胺剂量为研究方案剂量(至多5 µg/kg/min),非通用推荐。
- 常见陷阱:将术中研究方案剂量误作通用推荐;忽略开放标签设计对结果解读的限制;未评估心动过速风险。
指南或共识出处
- 原文未提及指南或共识名称;仅提及国际指南推荐多巴酚丁胺用于成人脓毒性休克伴心功能障碍和持续低灌注,基于极低确定性证据。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: International guidelines recommend dobutamine for management of septic shock and cardiac dysfunction with persistent hypoperfusion in adults based on very low-certainty evidence. Randomized trials are lacking on the effect of intraoperative dobutamine combined with norepinephrine vs norepinephrine on postoperative outcomes in patients with septic shock undergoing surgical source control.
OBJECTIVE: To determine whether intraoperative dobutamine combined with norepinephrine reduces acute kidney injury (AKI) within 7 postoperative days in patients with septic shock undergoing surgical source control.
DESIGN, SETTING, AND PARTICIPANTS: This randomized, open-label clinical trial in 39 tertiary hospitals in China enrolled adults with septic shock who were undergoing surgical source control between June 2024 and August 2025. Follow-up ended on November 15, 2025.
INTERVENTION: Intraoperative, intravenous infusion of dobutamine (up to 5 µg/kg/min) combined with norepinephrine vs norepinephrine alone.
MAIN OUTCOMES AND MEASURES: The primary outcome was new-onset AKI or worsening of preoperative AKI within 7 days after surgery, defined using Kidney Disease: Improving Global Outcomes (KDIGO) criteria. The 11 secondary outcomes included Sequential Organ Failure Assessment (SOFA) score on postoperative day 1 and urine output 1 hour post intervention.
RESULTS: Among 584 patients (median [IQR] age, 67.5 [55.0-76.0] years; 192 [32.9%] females), new-onset or worsening AKI within 7 postoperative days occurred in 22.8% (66/290) randomized to receive dobutamine plus norepinephrine vs 34.7% (102/294) randomized to receive norepinephrine alone (adjusted risk ratio [ARR], 0.64 [95% CI, 0.49-0.83]). No significant differences were observed in 9 of the 11 secondary outcomes. SOFA scores on postoperative day 1 (adjusted difference, -0.53 [95% CI, -0.98 to -0.07]) were lower and urine output 1 hour post intervention (adjusted difference, 0.55 [95% CI, 0.03 to 1.07] mL/kg/h) was higher in the dobutamine plus norepinephrine group. Stage 2 and 3 AKI were lower in the dobutamine plus norepinephrine group compared with the norepinephrine alone group (stage 2: 4.8% vs 9.9%; ARR, 0.48 [95% CI, 0.26-0.88]; stage 3: 7.9% vs 13.6%; ARR, 0.56 [95% CI, 0.35-0.91]). Tachycardia (heart rate >100/min) occurred more frequently in patients receiving dobutamine and norepinephrine than norepinephrine alone.
CONCLUSIONS AND RELEVANCE: Among adult patients with septic shock undergoing surgical source control, intraoperative dobutamine combined with norepinephrine reduced the incidence of new-onset or worsening AKI within 7 postoperative days compared with norepinephrine.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06462313.
参考来源
- Chu L, Xie G, Shi R, et al. Intraoperative Dobutamine Plus Norepinephrine to Prevent Postoperative Acute Kidney Injury in Septic Shock: A Randomized Clinical Trial. JAMA. 2026. PMID: 42872914. doi:10.1001/jama.2026.21322
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。